Literature DB >> 24481665

Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients.

Marco Montanaro1, Roberto Latagliata, Michele Cedrone, Antonio Spadea, Angela Rago, Jonny Di Giandomenico, Francesca Spirito, Raffaele Porrini, Marianna De Muro, Sabrina Crescenzi Leonetti, Nicoletta Villivà, Cinzia De Gregoris, Massimo Breccia, Enrico Montefusco, Cristina Santoro, Giuseppe Cimino, Ignazio Majolino, Maria Gabriella Mazzucconi, Giuliana Alimena, Alesssandro Andriani.   

Abstract

To identify prognostic factors affecting thrombosis-free survival (TFS) and overall survival (OS), we report the experience of a Regional cooperative group in a real-life cohort of 1,144 patients with essential thrombocythemia (ET) diagnosed from January 1979 to December 2010. There were 107 thrombotic events (9.4%) during follow-up [60 (5.3%) arterial and 47 (4.1%) venous thromboses]. At univariate analysis, risk factors for a shorter TFS were: age >60 years (P < 0.0054, 95% CI 1.18-2.6), previous thrombosis (P < 0.0001, 95% CI 1.58-4.52) and the presence of at least one cardiovascular risk factor (P = 0.036, 95% CI 1.15-3.13). Patients with a previous thrombosis occurred ≥24 months before ET diagnosis had a shorter TFS compared to patients with a previous thrombosis occurred <24 months (P = 0.0029, 95% CI 1.5-6.1); furthermore, patients with previous thrombosis occurred <24 months did not show a shorter TFS compared with patients without previous thrombosis (P = 0.303, 95% CI 0.64-3.21). At multivariate analysis for TFS, only the occurrence of a previous thrombosis maintained its prognostic impact (P = 0.0004, 95% CI 1.48-3.79, RR 2.36). The 10-year OS was 89.9% (95% CI 87.3-92.5): at multivariate analysis for OS, age >60 years (P < 0.0001), anemia (P < 0.0001), male gender (P = 0.0019), previous thromboses (P = 0.0344), and white blood cell >15 × 10(9) /l (P = 0.0370) were independent risk factors. Previous thrombotic events in ET patients are crucial for TFS but their importance seems related not to the occurrence per se but mainly to the interval between the event and the diagnosis.
Copyright © 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2014        PMID: 24481665     DOI: 10.1002/ajh.23685

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  12 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

2.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

3.  The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.

Authors:  Youwen Qin; Xiaorui Wang; Chuxian Zhao; Chun Wang; Yining Yang
Journal:  Int J Hematol       Date:  2015-05-22       Impact factor: 2.490

Review 4.  Epidemiology of MPN: what do we know?

Authors:  L A Anderson; M F McMullin
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 5.  Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.

Authors:  Bethany Samuelson; Chatree Chai-Adisaksopha; David Garcia
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

Review 6.  Advances and challenges in the management of essential thrombocythemia.

Authors:  Gunnar Birgegård
Journal:  Ther Adv Hematol       Date:  2015-06

7.  Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.

Authors:  Ayako Kamiunten; Kotaro Shide; Takuro Kameda; Masaaki Sekine; Yoko Kubuki; Masafumi Ito; Takanori Toyama; Noriaki Kawano; Kousuke Marutsuka; Kouichi Maeda; Masanori Takeuchi; Hiroshi Kawano; Seiichi Sato; Junzo Ishizaki; Keiichi Akizuki; Yuki Tahira; Haruko Shimoda; Tomonori Hidaka; Kiyoshi Yamashita; Hitoshi Matsuoka; Kazuya Shimoda
Journal:  Int J Hematol       Date:  2018-02-27       Impact factor: 2.490

8.  The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia.

Authors:  Danijela Lekovic; Mirjana Gotic; Natasa Milic; Predrag Miljic; Mirjana Mitrovic; Vladan Cokic; Ivo Elezovic
Journal:  Med Oncol       Date:  2014-09-16       Impact factor: 3.064

9.  Calreticulin Mutated Essential Thrombocythemia Presenting as Acute Coronary Syndrome.

Authors:  Bassel Nazha; Gwenalyn Garcia; Ruben Kandov; Marcel Odaimi
Journal:  Case Rep Hematol       Date:  2015-04-29

10.  A case of simultaneous acute cardio-cerebral infarction in a woman with essential thrombocythemia.

Authors:  LingQing Wang; Xiang Mao; JiPing Zheng; XingJian Gu; JianGuang Yang
Journal:  J Int Med Res       Date:  2019-08-20       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.